Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15252/emmm.201708763 http://scihub22266oqcxt.onion/10.15252/emmm.201708763 C5938617!5938617!29626112     free     free     free       EMBO+Mol+Med 2018 ; 10 (5): ä Nephropedia Template TP {{tp|p=29626112|t=2018. Amyloid blood biomarker detects Alzheimer s disease |pdf=|usr=}}{{29626112}} gab.com Text Amyloid blood biomarker detects Alzheimer s disease JO: EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=29626112 #FOAvip Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid?? (A?) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross?sectional BioFINDER cohort. In a further population?based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests. Twit Text FOAVip Amyloid blood biomarker detects Alzheimer s disease ????EMBO Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=29626112 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29626112 #FOAvip English Wikipedia <ref>{{Cite pmid|29626112}}</ref> Amyloid blood biomarker detects Alzheimer s disease #MMPMID29626112 Nabers A; Perna L; Lange J; Mons U; Schartner J; Güldenhaupt J; Saum K; Janelidze S; Holleczek B; Rujescu D; Hansson O; Gerwert K; Brenner H EMBO Mol Med 2018[May]; 10 (5): ä PMID29626112show ga Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy. Diagnostic tools for detection of AD are either invasive like cerebrospinal fluid (CSF) biomarkers or expensive such as positron emission tomography (PET) scanning. Here, we determine the secondary structure change of amyloid?? (A?) in human blood. This change used as blood amyloid biomarker indicates prodromal AD and correlates with CSF AD biomarkers and amyloid PET imaging in the cross?sectional BioFINDER cohort. In a further population?based longitudinal cohort (ESTHER), the blood biomarker detected AD several years before clinical diagnosis in baseline samples with a positive likelihood ratio of 7.9; that is, those who were diagnosed with AD over the years were 7.9 times more likely to test positive. This assay may open avenues for blood screening of early AD stages as a funnel for further more invasive and expensive tests. äAmyloid blood biomarker detects Alzheimer s disease (epmc).pdf DeepDyve Pubget Overpricing